Connect Biopharma Holdings Limited
News
(3)April 2026
CNTB's rademikibart Phase 2 Trials Continue with No Safety Issues
# 🧾 What This Document Is This is an SEC filing called an 8-K, which companies use to announce major news to investors. This specific filing includes a press release about a clinical trial update. It’s meant to keep the market informed about the progress of the company’s lead drug. 👉 **Why it mat
March 2026
Connect Biopharma Holdings Ltd — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which is like a major news alert a public company sends to the SEC and investors. This specific one includes a **press release** (the exhibit) where Connect Biopharma reports its 2025 financial results and gives a big update on its business prog
Connect Biopharma Holdings Ltd — 8-K Filing
# 🧾 What This Document Is This is a **Securities Purchase Agreement** filed as an exhibit to an 8-K report. Think of it as the detailed contract for a **private investment deal**. Connect Biopharma is selling new shares directly to a group of investors (not on the public stock market) to raise mone
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.